Ozempic, Mounjaro, Wegovy (and others) have been on everyone’s lips the last couple of years – brand names for some of the slew of new weight-loss jabs, medically known as Glucagon-Like-Peptide-1 (GLP-1) receptor agonists jabs (or GLP-1 for short). But as the NHS begins a bigger, phased, roll-out of GLP-1 medication, a bigger discussion needs to be had. What do these jabs mean for the UK agri-food system more widely, and our ability to shift diets towards those that are healthy, nutritious and sustainable? What about their influence on demand, product development, what we produce in response, farming systems and landscape shifts? What about long-term, lasting health implications? 

Our speaker, Victoria Stevens, of Bramble Partners (co-founded by Henry Dimbleby), has spent time looking into all of this. She delves into the topic for us to explore the risks, opportunities and key questions which remain from large-scale GLP-1 use and the resulting impact on our agri-food system.